The Annual General Meeting 2018 resolved to appoint Niklas Arnberg, Clas Runnberg, Sarah Fredriksson to Board members and Göran Wadell to Deputy.
Sarah Fredriksson, PhD, Chairman
PhD and M.Sc. from Lund University, Sweden. CEO of P.U.L.S. AB. Fredriksson has a background as founder and CEO of Genovis AB (listed on First North, Nasdaq OMX Nordic) and most recently CEO of Edvince AB. Currently board member of LU Holding and SwedenBIO and other board member assignments in the life science sector as well as of Sparbankstiftelsen Skånes Riskkapitalstiftelse. Former board member of AcuCort AB.
Niklas Arnberg, PhD, Member
Professor, Dept. of Virology, Inst. of Clinical Microbiology, Umeå University, Sweden. Discovered that sialic acid is the receptor for certain adenoviruses and defended his doctorial thesis in this subject in 2001. Arnberg has continued his research within this field and is one of the founders of Adenovir Pharma AB.
Clas Runnberg, Member
Market economist. Runnberg has held senior executive positions in several international medtech companies including Gambro and HemoCue in Sweden; Diatek Medical Technologies, Block Medical and HemoCue, Inc. in California, in the US. and Vidacare B.V. in the Netherlands. Presently he is an industrial advisor to the Swedish private equity fund Valedo, engaged in the Clinical Innovation Fellowships program at KTH, Stockholm and a board member of Medicon Bridge in Lund. Former chairman of P.U.L.S. AB.
Göran Wadell, MD, PhD, Deputy
Professor, Department of Virology, Umeå University, Sweden. Wadell is a recognized scientist in the field of adenovirus and one of the founders of Adenovir Pharma AB.